
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO

Fundamental Analysis



Revenue & Expenses Breakdown
Crescent Biopharma Inc (Pre-Reincorporation)
Balance Sheet Decomposition
Crescent Biopharma Inc (Pre-Reincorporation)
Current Assets | 11.1m |
Cash & Short-Term Investments | 10.7m |
Receivables | 136.6k |
Other Current Assets | 234.7k |
Free Cash Flow Analysis
Crescent Biopharma Inc (Pre-Reincorporation)
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Crescent Biopharma Inc (Pre-Reincorporation)
Revenue
|
0
USD
|
Operating Expenses
|
-32.5m
USD
|
Operating Income
|
-32.5m
USD
|
Other Expenses
|
-5.4m
USD
|
Net Income
|
-37.9m
USD
|
CBIO Profitability Score
Profitability Due Diligence
Crescent Biopharma Inc (Pre-Reincorporation)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Score
Crescent Biopharma Inc (Pre-Reincorporation)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.
CBIO Solvency Score
Solvency Due Diligence
Crescent Biopharma Inc (Pre-Reincorporation)'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Score
Crescent Biopharma Inc (Pre-Reincorporation)'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CBIO Price Targets Summary
Crescent Biopharma Inc (Pre-Reincorporation)
According to Wall Street analysts, the average 1-year price target for
CBIO
is 26.01 USD
with a low forecast of 22.22 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for CBIO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?